Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Current Opinion in Gastroenterology|May 25, 2013
Drug monitoring of biologics in inflammatory bowel diseaseAlexander Eser, Christian Primas, Walter ReinischBritish Journal of Clinical Pharmacology|November 13, 2020
Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease managementAna-Marija Grisic, Alexander Eser, Wilhelm Huisinga, et al.Blood|May 24, 2003
Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitroLeopold Oehler, Eva Jaeger, Alexander Eser, et al.The American Journal of Gastroenterology|July 18, 2023
P010 Precision Dosing Tool Forecasts Trough Infliximab and Associates With Disease Status in Inflammatory Bowel DiseasesThierry Dervieux, Christian Primas, John Panetta, et al.Journal of Clinical Pharmacology|September 9, 2020
Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody DetectionAlexander Eser, Walter Reinisch, Stefan Schreiber, et al.Scandinavian Journal of Gastroenterology|February 21, 2015
Early recognition of possible pitfalls in histological diagnosis of celiac diseaseWolfgang Eigner, Friedrich Wrba, Andreas Chott, et al.European Journal of Clinical Investigation|October 8, 2016
Platelets Toll-like receptor-4 in Crohns diseaseWerner Schmid, Gottfried Novacek, Harald Vogelsang, et al.Journal of Clinical Medicine|June 24, 2022
Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel DiseasesChristian Primas, Walter Reinisch, John C Panetta, et al.Journal of Clinical Pharmacology|January 31, 2018
Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard SystemAlexander Eser, Christian Primas, Sieglinde Reinisch, et al.Inflammatory Bowel Diseases|July 22, 2015
Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa StudyAlexander Eser, Jean-Frederic Colombel, Paul Rutgeerts, et al.Pageof 2